Probiotec Ltd
ASX:PBP

Watchlist Manager
Probiotec Ltd Logo
Probiotec Ltd
ASX:PBP
Watchlist
Price: 2.98 AUD Market Closed
Market Cap: 242.3m AUD
Have any thoughts about
Probiotec Ltd?
Write Note

Relative Value

The Relative Value of one PBP stock under the Base Case scenario is 5.61 AUD. Compared to the current market price of 2.98 AUD, Probiotec Ltd is Undervalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PBP Relative Value
Base Case
5.61 AUD
Undervaluation 47%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
42
vs Industry
68
Median 3Y
1
Median 5Y
1.1
Industry
2.5
Forward
1
vs History
30
vs Industry
17
Median 3Y
20.6
Median 5Y
25.5
Industry
21.4
Forward
16.4
vs History
15
vs Industry
27
Median 3Y
11.1
Median 5Y
12.2
Industry
16
vs History
1
vs Industry
7
Median 3Y
42.8
Median 5Y
21.1
Industry
23.3
vs History
1
vs Industry
29
Median 3Y
2.4
Median 5Y
2.3
Industry
2.1
vs History
46
vs Industry
62
Median 3Y
1.3
Median 5Y
1.4
Industry
2.6
Forward
1.3
vs History
49
vs Industry
43
Median 3Y
4.4
Median 5Y
4.7
Industry
5.1
vs History
39
vs Industry
24
Median 3Y
14.5
Median 5Y
15.3
Industry
13.7
Forward
7.8
vs History
39
vs Industry
28
Median 3Y
14.5
Median 5Y
15.3
Industry
16.7
Forward
12.3
vs History
14
vs Industry
23
Median 3Y
12.3
Median 5Y
14.1
Industry
15.1
vs History
1
vs Industry
7
Median 3Y
30.1
Median 5Y
30.1
Industry
18.9
vs History
1
vs Industry
42
Median 3Y
1.3
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

PBP Competitors Multiples
Probiotec Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Probiotec Ltd
ASX:PBP
242.3m AUD 1.1 27.9 15.4 15.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
726.7B USD 17.8 86.8 46.7 52.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.1 28.8 20 22.9
US
Johnson & Johnson
NYSE:JNJ
345.8B USD 3.9 23.6 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
252.5B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
205.3B CHF 3.5 17.9 10 11.9
UK
AstraZeneca PLC
LSE:AZN
166.1B GBP 4.2 32.3 169.7 254.3
CH
Novartis AG
SIX:NOVN
174B CHF 3.9 10.9 9.5 13.2
US
Pfizer Inc
NYSE:PFE
152.4B USD 2.5 35.8 10.6 16.1
P/S Multiple
Revenue Growth P/S to Growth
AU
Probiotec Ltd
ASX:PBP
Average P/S: 382 942
1.1
8%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
7%
601 676.1
US
Eli Lilly and Co
NYSE:LLY
17.8
28%
0.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
21%
0.5
US
Johnson & Johnson
NYSE:JNJ
3.9
4%
1
US
Merck & Co Inc
NYSE:MRK
4
6%
0.7
CH
Roche Holding AG
SIX:ROG
3.5
5%
0.7
UK
AstraZeneca PLC
LSE:AZN
4.2
10%
0.4
CH
Novartis AG
SIX:NOVN
3.9
6%
0.6
US
Pfizer Inc
NYSE:PFE
2.5
3%
0.8
P/E Multiple
Earnings Growth PEG
AU
Probiotec Ltd
ASX:PBP
Average P/E: 31.6
27.9
20%
1.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
86.8
76%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
28.8
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.6
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
17.9
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
32.3
40%
0.8
CH
Novartis AG
SIX:NOVN
10.9
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.8
102%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Probiotec Ltd
ASX:PBP
Average EV/EBITDA: 415
15.4
35%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.7
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.4
4%
2.9
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10
7%
1.4
UK
AstraZeneca PLC
LSE:AZN
169.7
18%
9.4
CH
Novartis AG
SIX:NOVN
9.5
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Probiotec Ltd
ASX:PBP
Average EV/EBIT: 1 811.6
15.4
16%
1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.1
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
22.9
22%
1
US
Johnson & Johnson
NYSE:JNJ
14.8
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
11.9
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
254.3
32%
7.9
CH
Novartis AG
SIX:NOVN
13.2
17%
0.8
US
Pfizer Inc
NYSE:PFE
16.1
19%
0.8